Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 7 | 2021 | 466 | 2.010 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 962 | 1.260 |
Why?
|
| Drug Prescriptions | 2 | 2021 | 187 | 1.250 |
Why?
|
| Drug Overdose | 3 | 2018 | 117 | 0.940 |
Why?
|
| Physostigmine | 1 | 2022 | 4 | 0.880 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2021 | 2 | 0.830 |
Why?
|
| Delirium | 1 | 2022 | 52 | 0.830 |
Why?
|
| Prescription Drug Misuse | 2 | 2018 | 23 | 0.780 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 46 | 0.770 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 87 | 0.750 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 21 | 0.710 |
Why?
|
| Poisoning | 1 | 2020 | 28 | 0.710 |
Why?
|
| Opioid-Related Disorders | 3 | 2020 | 428 | 0.610 |
Why?
|
| Information Dissemination | 1 | 2018 | 109 | 0.590 |
Why?
|
| Oxycodone | 2 | 2014 | 32 | 0.580 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 120 | 0.520 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 722 | 0.520 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 145 | 0.510 |
Why?
|
| Toxicology | 1 | 2014 | 33 | 0.480 |
Why?
|
| Oxymorphone | 1 | 2013 | 6 | 0.460 |
Why?
|
| Emergency Medicine | 3 | 2021 | 178 | 0.430 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 46 | 0.430 |
Why?
|
| Massachusetts | 4 | 2021 | 2101 | 0.330 |
Why?
|
| Faculty, Medical | 3 | 2021 | 203 | 0.330 |
Why?
|
| Fentanyl | 2 | 2020 | 65 | 0.330 |
Why?
|
| Humans | 20 | 2023 | 55553 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2021 | 5480 | 0.240 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 7 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 20 | 0.220 |
Why?
|
| Rivastigmine | 1 | 2022 | 2 | 0.220 |
Why?
|
| Female | 11 | 2023 | 29015 | 0.220 |
Why?
|
| Acetylcholinesterase | 1 | 2022 | 15 | 0.220 |
Why?
|
| Muscarinic Antagonists | 1 | 2022 | 16 | 0.220 |
Why?
|
| Vasodilator Agents | 1 | 2023 | 56 | 0.220 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2022 | 41 | 0.210 |
Why?
|
| Research Support as Topic | 2 | 2019 | 43 | 0.210 |
Why?
|
| Amnesia | 2 | 2020 | 11 | 0.210 |
Why?
|
| Middle Aged | 7 | 2023 | 14976 | 0.190 |
Why?
|
| Physicians, Women | 1 | 2021 | 41 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 16 | 0.190 |
Why?
|
| Forecasting | 1 | 2021 | 207 | 0.180 |
Why?
|
| Uganda | 1 | 2020 | 34 | 0.180 |
Why?
|
| Financing, Government | 1 | 2019 | 32 | 0.170 |
Why?
|
| Adult | 8 | 2023 | 14645 | 0.170 |
Why?
|
| Male | 9 | 2023 | 25479 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 50 | 0.170 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2018 | 27 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 110 | 0.160 |
Why?
|
| Efficiency | 1 | 2018 | 42 | 0.160 |
Why?
|
| Writing | 1 | 2018 | 39 | 0.160 |
Why?
|
| Hospitals, Community | 1 | 2018 | 66 | 0.160 |
Why?
|
| Rural Population | 1 | 2020 | 182 | 0.160 |
Why?
|
| Drug Approval | 1 | 2017 | 28 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 98 | 0.140 |
Why?
|
| Insufflation | 2 | 2013 | 10 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 89 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4700 | 0.130 |
Why?
|
| Infant | 1 | 2020 | 1500 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 2302 | 0.130 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Tonsillectomy | 1 | 2014 | 8 | 0.120 |
Why?
|
| Codeine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Adolescent | 3 | 2021 | 5668 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2020 | 1813 | 0.120 |
Why?
|
| Women's Health | 1 | 2017 | 412 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 86 | 0.110 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 15 | 0.110 |
Why?
|
| Universities | 1 | 2014 | 148 | 0.110 |
Why?
|
| Minocycline | 1 | 2012 | 22 | 0.110 |
Why?
|
| Aged | 4 | 2021 | 12313 | 0.110 |
Why?
|
| Nasopharynx | 1 | 2012 | 19 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2012 | 50 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2012 | 74 | 0.100 |
Why?
|
| Young Adult | 1 | 2021 | 3992 | 0.100 |
Why?
|
| Child | 3 | 2019 | 4161 | 0.100 |
Why?
|
| Vertebral Artery | 1 | 2010 | 23 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 807 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 235 | 0.090 |
Why?
|
| Internet | 1 | 2013 | 454 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 303 | 0.080 |
Why?
|
| United States | 2 | 2019 | 7082 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2013 | 4550 | 0.070 |
Why?
|
| Angiotensins | 1 | 2023 | 5 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2023 | 20 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2023 | 172 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2023 | 131 | 0.050 |
Why?
|
| Hypoxia | 1 | 2023 | 88 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 416 | 0.050 |
Why?
|
| Career Mobility | 1 | 2021 | 56 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2020 | 179 | 0.050 |
Why?
|
| Syndrome | 1 | 2020 | 174 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2019 | 20 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 613 | 0.040 |
Why?
|
| Leadership | 1 | 2021 | 203 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 95 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 225 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 113 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 641 | 0.040 |
Why?
|
| Mentors | 1 | 2018 | 113 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 913 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 239 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 1158 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 649 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1177 | 0.030 |
Why?
|
| Analgesics | 1 | 2016 | 95 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 362 | 0.030 |
Why?
|
| Pain Management | 1 | 2016 | 129 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2012 | 23 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 130 | 0.030 |
Why?
|
| Necrosis | 1 | 2012 | 126 | 0.030 |
Why?
|
| Parkinson Disease | 1 | 2012 | 85 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 4682 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 1757 | 0.010 |
Why?
|